MAPKAPK2 and central nervous system cancer: The survival analyses of subgroups of glioma indicated that high levels of MAPKAPK2 predict poor prognosis in grade 2 and grade 3 but not grade 4, which might be mainly caused by the limited number of patients with short survival time and low survival rate enrolled in the grade 4 cohort.